Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14862556 | 1.00 | HTT (0.43) | HTTADAMTS4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20067564 | 0.89 | USP2 (0.45) | HTTADAMTS4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL19026344 | 0.89 | RAB9A (0.46) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL19026343 | 0.89 | RAB9A (0.46) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL23933133 | 0.89 | RAB9A (0.48) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL20580635 | 0.89 | RAB9A (0.48) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL17595434 | 0.88 | HTT (0.43) | HTTSMN1; SMN2NPC1RAB9AUSP2 | |
| SCHEMBL17595432 | 0.88 | HTT (0.43) | HTTSMN1; SMN2NPC1RAB9AUSP2 | |
| SCHEMBL22561334 | 0.88 | ADAMTS4 (0.41) | HTTADAMTS4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20733348 | 0.88 | ADAMTS4 (0.41) | HTTADAMTS4SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-12011485-B2 | Sulfomaleimide-based linkers and corresponding conjugates | PIERRE FABRE MEDICAMENT (FR) | 2024-06-18 | — | — | US | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3900742-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-04-02 | — | — | US | disclosed |
| EP-4321523-A2 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308170-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | Seagen Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | CELLERANT THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3209334-A2 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Igenica Biotherapeutics, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-3191502-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | Seattle Genetics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3191490-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Medimmune Limited (GB) | 2017-07-19 | — | — | EP | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2016040684-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016038383-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177795-A1 | ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS | BCL6B, HTR2B, IDO1 | HTT 1009/4885ADAMTS4 3765/4885SMN1; SMN2 2177/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | HTT 1193/4885ADAMTS4 2361/4885SMN1; SMN2 4757/4885 |
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | HTT 4107/4885ADAMTS4 3015/4885SMN1; SMN2 305/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | HTT 2242/4885ADAMTS4 2964/4885SMN1; SMN2 3729/4885 |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | HTT 1048/4885ADAMTS4 2101/4885SMN1; SMN2 875/4885 |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | HTT 3874/4885ADAMTS4 4268/4885SMN1; SMN2 2768/4885 |
| US-12011485-B2 | Sulfomaleimide-based linkers and corresponding conjugates | CSGALNACT1, CD44, IGLV6-57 | HTT 3522/4885ADAMTS4 1905/4885SMN1; SMN2 1601/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | HTT 851/4885ADAMTS4 865/4885SMN1; SMN2 3157/4885 |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BOD1L1, GABRA1 | HTT 3265/4885ADAMTS4 4301/4885SMN1; SMN2 2532/4885 |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SDCBP, DCLRE1A, BCR | HTT 3153/4885ADAMTS4 1393/4885SMN1; SMN2 3012/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | HTT 1146/4885ADAMTS4 132/4885SMN1; SMN2 2707/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | HTT 359/4885ADAMTS4 4397/4885SMN1; SMN2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.